Works matching IS 1462-8902 AND VI 18 AND IP 5 AND DT 2016

Results: 16

Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 463, doi. 10.1111/dom.12629

By:

Pettus, J.;
McNabb, B.;
Eckel, R. H.;
Skyler, J. S.;
Dhalla, A.;
Guan, S.;
Jochelson, P.;
Belardinelli, L.;
Henry, R. H.

Publication type:

Article

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 533, doi. 10.1111/dom.12640

By:

Milicevic, Z.;
Anglin, G.;
Harper, K.;
Konrad, R. J.;
Skrivanek, Z.;
Glaesner, W.;
Karanikas, C. A.;
Mace, K.

Publication type:

Article

Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 537, doi. 10.1111/dom.12641

By:

Darsalia, V.;
Larsson, M.;
Lietzau, G.;
Nathanson, D.;
Nyström, T.;
Klein, T.;
Patrone, C.

Publication type:

Article

Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 500, doi. 10.1111/dom.12642

By:

Aronson, R.;
Reznik, Y.;
Conget, I.;
Castañeda, J. A.;
Runzis, S.;
Lee, S. W.;
Cohen, O.

Publication type:

Article

L-arginine promotes gut hormone release and reduces food intake in rodents.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 508, doi. 10.1111/dom.12644

By:

Alamshah, A.;
McGavigan, A. K.;
Spreckley, E.;
Kinsey‐Jones, J. S.;
Amin, A.;
Tough, I. R.;
O'Hara, H. C.;
Moolla, A.;
Banks, K.;
France, R.;
Hyberg, G.;
Norton, M.;
Cheong, W.;
Lehmann, A.;
Bloom, S. R.;
Cox, H. M.;
Murphy, K. G.

Publication type:

Article

Prevention of antibiotic-associated metabolic syndrome in mice by intestinal alkaline phosphatase.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 519, doi. 10.1111/dom.12645

By:

Economopoulos, K. P.;
Ward, N. L.;
Phillips, C. D.;
Teshager, A.;
Patel, P.;
Mohamed, M. M.;
Hakimian, S.;
Cox, S. B.;
Ahmed, R.;
Moaven, O.;
Kaliannan, K.;
Alam, S. N.;
Haller, J. F.;
Goldstein, A. M.;
Bhan, A. K.;
Malo, M. S.;
Hodin, R. A.

Publication type:

Article

Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. A Focus on Early Phase Clinical Studies. Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch (eds) Springer 2015, ISBN 978-1-4471-4919-4.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 544, doi. 10.1111/dom.12664

By:

Idris, Iskandar

Publication type:

Article

Diabetes, Obesity and Metabolism.

Published in:: Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 437, doi. 10.1111/dom.12561
Publication type:: Article

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 528, doi. 10.1111/dom.12631

By:

Hong, S.;
Park, C.‐Y.;
Han, K. A.;
Chung, C. H.;
Ku, B. J.;
Jang, H. C.;
Ahn, C. W.;
Lee, M.‐K.;
Moon, M. K.;
Son, H. S.;
Lee, C. B.;
Cho, Y.‐W.;
Park, S.‐W.

Publication type:

Article

A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes ( AWARD-8).

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 475, doi. 10.1111/dom.12634

By:

Dungan, K. M.;
Weitgasser, R.;
Perez Manghi, F.;
Pintilei, E.;
Fahrbach, J. L.;
Jiang, H. H.;
Shell, J.;
Robertson, K. E.

Publication type:

Article

Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 ( HSD1) inhibitor in humans: liver and adipose tissue 11β- HSD1 inhibition after acute and multiple administrations over 2 weeks.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 483, doi. 10.1111/dom.12635

By:

Freude, S.;
Heise, T.;
Woerle, H.‐J.;
Jungnik, A.;
Rauch, T.;
Hamilton, B.;
Schölch, C.;
Huang, F.;
Graefe‐Mody, U.

Publication type:

Article

Therapeutic potential of Takeda- G-protein-receptor-5 ( TGR5) agonists. Hope or hype?

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 439, doi. 10.1111/dom.12636

By:

Hodge, R. J.;
Nunez, D. J.

Publication type:

Article

Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 444, doi. 10.1111/dom.12637

By:

Mikkelsen, K. H.;
Allin, K. H.;
Knop, F. K.

Publication type:

Article

Exposure-response analyses of liraglutide 3.0 mg for weight management.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 491, doi. 10.1111/dom.12639

By:

Wilding, J. P. H.;
Overgaard, R. V.;
Jacobsen, L. V.;
Jensen, C. B.;
le Roux, C. W.

Publication type:

Article

Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 454, doi. 10.1111/dom.12652

By:

DeFronzo, R. A.;
Chilton, R.;
Norton, L.;
Clarke, G.;
Ryder, R. E. J.;
Abdul‐Ghani, M.

Publication type:

Article

News and Views.

Published in:

Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 542, doi. 10.1111/dom.12659

By:

Idris, Iskandar

Publication type:

Article